Vestibular schwannoma growth rates in Neurofibromatosis type 2 Natural History Consortium subjects

Otology and Neurotology

Volumn 25, Issue 5, 2004, Pages 811-817

  Slattery III, William H ^a   Fisher, Laurel M ^a   Iqbal, Zarina ^a   Oppenhiemer, Mark ^a  

^a HOUSE EAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CALCULATION; EVALUATION; FEMALE; FOLLOW UP; GROWTH RATE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GROWTH; TUMOR VOLUME; VESTIBULAR SCHWANNOMA;

ADULT; ANALYSIS OF VARIANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RETROSPECTIVE STUDIES;

EID: 4544322397     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200409000-00027     Document Type: Article

References (30)

1. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of NF1 and NF2. JAMA 1997;278:51-7.
2. Good WV, Erodsky MC, Edwards MS, et al. Bilateral retinal hamartomas in neurofibromatosis type 2. Br J Ophthalmol 1991;75:190.
3. Landau K, Yasargil GM. Ocular fundus in neurofibromatosis type 2. Br J Ophthalmol 1993;77:646-9.
4. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
5. Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol 1995;120:634-41.
6. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
7. Lim DJ, Rubenstein AE, Evans DG, et al. Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet 2000;14:63-106.
8. Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 1995;165:951-5.
9. Evans DG, Mason S, Huson SM, et al. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry 1997;62:361-6.
10. Mautner VF, Lindenau M, Baser ME, et al. Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997;133:1539-43.
11. Baser ME, Mautner VF, Ragge NK, et al. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 1996;47:1269-77.
12. Bijlsma EK, Merel P, Fleury P, et al. Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. Hum Genet 1995;96:1-5.
13. Evans DG, Wallace AJ, Wu CL, et al. Somatic mosaicisnr: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998;63:727-36.
14. Gardner WJ, Frazier CH. Bilateral acoustic neurofibromas: A clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. Arch Neurol Psychiatr 1930;23:266-302.
15. Kluwe L, Mautner VF. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996;97:224-7.
16. Mautner VF, Baser ME, Kluwe L. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 1996;98:203-6.
17. Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45:1314-22.
18. Welling DB. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas). Laryngoscope 1998;108:178-89.
19. Wishart JH. Case of tumors of the skull, dura mater and brain. Edinburgh Med Surg J 1822;18:393-7.
20. Mautner VF, Lindenau M, Koppen J, Hazim W, Kluwe L. [Type 2 neurofibromatosis without acoustic neuroma]. Zentralbl Neurochir 1995;56:83-7.
21. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5; discussion 885-6.
22. Fucci MJ, Buchman CA, Brackmann DE, et al. Acoustic tumor growth: implications for treatment choices. Am J Otol 1999;20:495-9.
23. Hoistad DL, Melnik G, Mamikoglu B, et al. Update on conservative management of acoustic neuroma. Otol Neurotol 2001;22:682-5.
24. Irving RM, Harada T, Moffat DA, et al. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma. Am J Otol 1997;18:754-60.
25. Mirz F, Jorgensen B, Fiirgaard B, et al. Investigations into the natural history of vestibular schwannomas. Clin Otolaryngol 1999;24:13-8.
26. Nutik SL, Babb MJ. Determinants of tumor size and growth in vestibular schwannomas. J Neurosurg 2001;94:922-6.
27. Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope 2000;110:497-508.
28. Mautner VF, Baser ME, Thakkar SD, et al. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg 2002;96:223-8.
29. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 2002;96:217-22.
30. Rosenberg, S., Silverstein, H., Gordon, et al. A comparison of growth rates of acoustic neuromas: Non-surgical patients vs subtotal resection. Oto Head Neck Surgery 1993;109:482-7.